20 States and DC Screening Newborns for Pompe as Efforts Continue for More, MDA Says

Grace Frank avatar

by Grace Frank |

Share this article:

Share article via email
newborn screening

A map showing states screening for SMA, Pompe, or both diseases as of February 2020. (Courtesy of MDA)

Across the U.S., 20 states are now screening newborns for Pompe, the most recent neuromuscular disease added to a list of serious genetic disorders for which infants can be tested shortly after birth, advocacy officers at the Muscular Dystrophy Association (MDA) said.

Washington is the latest to start statewide screening for Pompe, which began in October 2019.

“The reason that we are such champions of newborn screening is that every baby has the opportunity to be identified at birth” and get into treatment “as quickly as possible,” Kristin Stephenson, an executive vice president and chief advocacy and care services officer for the MDA, said in an interview with Pompe Disease News. “It’s really a very effective vehicle.”

Pompe/SMA newborn screening

A map showing states screening for SMA, Pompe, or both diseases as of February 2020. (Courtesy of MDA)

The 20 states with Pompe screening programs in place are: California, Delaware, Illinois, Kentucky, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, New York, Ohio, Oregon, Pennsylvania, Rhode Island, Tennessee, Vermont, Virginia, and Washington.

The District of Columbia also runs a Pompe screening program.

Screening involves collecting a spot of blood from a newborn, and running it through tests that check, say, for protein or enzyme activity.

Spinal muscular atrophy (SMA), which affects motor neurons, is the only other disorder among the 40 distinct, and often rare, neuromuscular diseases covered by MDA on this federal list, known as the Recommended Uniform Screening Panel (RUSP).

Not coincidentally, Pompe and SMA also are the only two of these 40 disorders with disease-modifying treatments — approved therapies that do more than ease a patient’s symptoms.

Pompe joined the RUSP in June 2015, two years after its addition was advised. Its sole modifying treatment to date, Lumizyme (by Sanofi Genzyme), was approved by the U.S. Food and Drug Administration (FDA) in May 2010.

SMA was added to the RUSP in February 2018, a little over a year after Spinraza, by Biogen, became its first disease-modifying treatment.

“It really turns on when therapies are available,” as a targeted treatment is a “necessary criteria” for a disease to be added, Stephenson said. “The speed at which newborn screening will be a viable option for diseases we cover directly correlates to the speed at which therapeutic development happens.”

Few question the importance of newborn screening for identifying in the hours after birth a progressive and often life-threatening disease, allowing a child to be treated before irreparable damage is done.

But the cost of screening each of the roughly 4 million babies born in the U.S. each year can be considerable, largely assumed by each state. States, as a result, individually decide whether to screen for each of the 35 diseases listed on RUSP, typically either by legislative action or a governor issuing an executive order.

Only California requires statewide screening to begin getting underway within two years of a disease coming onto RUSP, said Brittany Johnson Hernandez, the MDA’s senior director of policy and advocacy.

Florida also is unusual in having some sort of required statewide implementation, but this demand only kicks in after state leaders agree to adopt a recommendation. As a result, Florida is only starting to put Pompe screening into place.

Grants are available from the federal government, Stephenson said, but they’re “not always as robust as they need to be for implementation, and states have to find the funding for this.”

For this fiscal year, the Centers for Disease Control and Prevention (CDC) was allocated $17 million for its newborn screening program, Hernandez said, and the Health Resources and Services Administration (HRSA) $17.8 million to implement such screening nationwide. The HRSA is part of the Public Health Service, charged with providing health care to people who are geographically isolated, or economically or medically vulnerable.

Costs also vary greatly among states thinking of starting to screen babies for a given disease. Factors that can include new machinery needed, the capacity of existing screening labs, and the degree of additional staff training necessary play into each state’s costs.

Other considerations for states are the “efficacy and availability of [approved] medications, and how many [healthcare] providers are available to treat children identified,” Stephenson said.

That’s where the MDA comes in to encourage state action, she added. Its MDA Care Centers have teams specialized in neuromuscular disease diagnosis, treatment, and management set up in 150 clinics across the U.S., with at least one such center in every state.

Getting a disease to be considered by members of the federal committee whose opinions determine the RUSP — called the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children, or SACHDNC — is itself a rigorous and costly process.

Petitioners need to present proof of the effectiveness and availability of approved treatments, a validated laboratory test for a screen, and a study of the estimated population with the disease. The committee, after a review and independent evaluation, then makes recommendations to the secretary of the Department of Health and Human Services (HHS), who makes the final decisions.

States are not bound to screen for any disease listed on the RUSP.

No new disorders are coming onto the RUSP right now, however, because the U.S. Senate failed to reauthorize the Newborn Screening Saves Lives Act before it expired on Sept. 30, 2019. Allocated funding for screenings remains in place, but no work is being done by the federal committee that advises on diseases for the RUSP.

“We are working with partners across the patient advocacy space and researchers to try and move forward the authorization,” Hernandez said. “It’s really a matter of finding an appropriate vehicle [Senate bill] in the coming months.”

This ad-hoc patient group coalition also is petitioning Alex Azar, the HHS secretary, to issue an executive order to restart the committee, allowing it to meet. The groups argue that he has the necessary statutory authority to do so.

“The program, though not authorized right now, still has funding appropriated for it, so ongoing work of national program is still active,” Stephenson said.